Pegvorhyaluronidase alfa

• CAT Number: I034355
• CAS Number: 1620390-06-8
• Molecular Formula: C13H26N2O5
• Molecular Weight: 290.36
• Purity: 98%
• Synonyms: Pegvorhyaluronidase alfa
• Solubility: To be determined
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: N6-(4-(2-methoxyethoxy)butanoyl)-L-lysine
• InChI: InChI=1S/C13H26N2O5/c1-19-9-10-20-8-4-6-12(16)15-7-3-2-5-11(14)13(17)18/h11H,2-10,14H2,1H3,(H,15,16)(H,17,18)/t11-/m0/s1
• InChIKey: RMCUGWXDCKNMLC-NSHDSACASA-N
• SMILES: COCCOCCCC(NCCCC[C@@H](C(O)=O)N)=O

Pegvorhyaluronidase alfa (Cat No.: I034355) is a PEGylated recombinant human hyaluronidase enzyme designed to degrade hyaluronan, a major component of the extracellular matrix in tumors. By breaking down hyaluronan, it enhances the penetration and efficacy of co-administered anticancer therapies. Used in oncology, especially pancreatic and other solid tumors, it improves drug delivery and reduces tumor interstitial pressure. The PEGylation increases its half-life and stability. Pegvorhyaluronidase alfa is being evaluated in combination therapies to overcome tumor resistance and improve treatment outcomes in cancer patients.

Reference

1: Van Cutsem E, Tempero MA, Sigal D, Oh DY, Fazio N, Macarulla T, Hitre E, Hammel P, Hendifar AE, Bates SE, Li CP, Hingorani SR, de la Fouchardiere C, Kasi A, Heinemann V, Maraveyas A, Bahary N, Layos L, Sahai V, Zheng L, Lacy J, Park JO, Portales F, Oberstein P, Wu W, Chondros D, Bullock AJ; HALO 109-301 Investigators. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab- Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. J Clin Oncol. 2020 Sep 20;38(27):3185-3194. doi: 10.1200/JCO.20.00590. Epub 2020 Jul 24. PMID: 32706635; PMCID: PMC7499614.
2: Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol. 2020 Aug;17(8):487-505. doi: 10.1038/s41575-020-0300-1. Epub 2020 May 11. PMID: 32393771; PMCID: PMC8284850.
3: Sugarman R, Patel R, Sharma S, Plenker D, Tuveson D, Saif MW. Pharmacokinetics and pharmacodynamics of new drugs for pancreatic cancer. Expert Opin Drug Metab Toxicol. 2019 Jul;15(7):541-552. doi: 10.1080/17425255.2019.1637417. Epub 2019 Jul 5. PMID: 31241371.
4: Hingorani SR, Zheng L, Bullock AJ, Seery TE, Harris WP, Sigal DS, Braiteh F, Ritch PS, Zalupski MM, Bahary N, Oberstein PE, Wang-Gillam A, Wu W, Chondros D, Jiang P, Khelifa S, Pu J, Aldrich C, Hendifar AE. HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab- Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. J Clin Oncol. 2018 Feb 1;36(4):359-366. doi: 10.1200/JCO.2017.74.9564. Epub 2017 Dec 12. PMID: 29232172.
5: Wang S, Bager CL, Karsdal MA, Chondros D, Taverna D, Willumsen N. Blood-based extracellular matrix biomarkers as predictors of survival in patients with metastatic pancreatic ductal adenocarcinoma receiving pegvorhyaluronidase alfa. J Transl Med. 2021 Jan 21;19(1):39. doi: 10.1186/s12967-021-02701-z. PMID: 33478521; PMCID: PMC7819178.
6: Hakim N, Patel R, Devoe C, Saif MW. Why HALO 301 Failed and Implications for Treatment of Pancreatic Cancer. Pancreas (Fairfax). 2019;3(1):e1-e4. doi: 10.17140/POJ-3-e010. Epub 2019 Dec 20. PMID: 32030361; PMCID: PMC7003617.
7: Clift R, Souratha J, Garrovillo SA, Zimmerman S, Blouw B. Remodeling the Tumor Microenvironment Sensitizes Breast Tumors to Anti-Programmed Death-Ligand 1 Immunotherapy. Cancer Res. 2019 Aug 15;79(16):4149-4159. doi: 10.1158/0008-5472.CAN-18-3060. Epub 2019 Jun 27. PMID: 31248966.
8: Heineman T, Baumgart M, Nanavati C, Gabrail N, Van Wart SA, Mager DE, Maneval DC, Fathallah AM, Sekulovich RE. Safety and pharmacokinetics of docetaxel in combination with pegvorhyaluronidase alfa in patients with non-small cell lung cancer. Clin Transl Sci. 2021 May 13. doi: 10.1111/cts.13041. Epub ahead of print. PMID: 33982408.
9: Cao J, Pickup S, Clendenin C, Blouw B, Choi H, Kang D, Rosen M, O’Dwyer PJ, Zhou R. Dynamic Contrast-enhanced MRI Detects Responses to Stroma-directed Therapy in Mouse Models of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2019 Apr 1;25(7):2314-2322. doi: 10.1158/1078-0432.CCR-18-2276. Epub 2018 Dec 26. PMID: 30587546; PMCID: PMC6445712.
10: Zhao C, Thompson BJ, Chen K, Gao F, Blouw B, Marella M, Zimmerman S, Kimbler T, Garrovillo S, Bahn J, Huang L, Huang Z, Shepard HM, Rosengren S, Thanos CD, Maneval DC. The growth of a xenograft breast cancer tumor model with engineered hyaluronan-accumulating stroma is dependent on hyaluronan and independent of CD44. Oncotarget. 2019 Nov 12;10(61):6561-6576. doi: 10.18632/oncotarget.27302. PMID: 31762938; PMCID: PMC6859925.